Maat Pharma SA (MAAT) - Cash Flow Conversion Efficiency

Latest as of June 2025: -1.853x

Based on the latest financial reports, Maat Pharma SA (MAAT) has a cash flow conversion efficiency ratio of -1.853x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-15.37 Million ≈ $-17.97 Million USD) by net assets (€8.29 Million ≈ $9.70 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Maat Pharma SA to measure how much of total assets are equity-financed.

Maat Pharma SA - Cash Flow Conversion Efficiency Trend (2017–2024)

This chart illustrates how Maat Pharma SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore MAAT cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.

Maat Pharma SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Maat Pharma SA ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
ImmunoPrecise Antibodies Ltd. NASDAQ:HYFT	-0.162x
Kayseri Seker Fabrikasi AS IS:KAYSE	0.171x
SEOWONINTECH.Co.Ltd KQ:093920	0.008x
Korea Cable T.V Chung-Buk System Co. Ltd. KQ:066790	-0.007x
Rottneros AB ST:RROS	-0.028x
Meta Biomed Co. Ltd KQ:059210	0.009x
Bekasi Fajar Industrial Estate JK:BEST	0.001x
Cimbeton Hazirbeton ve Prefabrik Yapi Elemanlari Sanayi ve Ticaret AS IS:CMBTN	0.316x

Annual Cash Flow Conversion Efficiency for Maat Pharma SA (2017–2024)

The table below shows the annual cash flow conversion efficiency of Maat Pharma SA from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Maat Pharma SA.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€10.34 Million ≈ $12.08 Million	€-22.04 Million ≈ $-25.77 Million	-2.132x	-133.76%
2023-12-31	€20.47 Million ≈ $23.93 Million	€-18.67 Million ≈ $-21.83 Million	-0.912x	-94.04%
2022-12-31	€26.81 Million ≈ $31.34 Million	€-12.61 Million ≈ $-14.74 Million	-0.470x	-136.32%
2021-12-31	€39.86 Million ≈ $46.60 Million	€-7.93 Million ≈ $-9.27 Million	-0.199x	+45.47%
2020-12-31	€15.94 Million ≈ $18.63 Million	€-5.81 Million ≈ $-6.80 Million	-0.365x	-133.18%
2019-12-31	€-4.57 Million ≈ $-5.34 Million	€-5.02 Million ≈ $-5.87 Million	1.099x	+136.04%
2018-12-31	€1.27 Million ≈ $1.48 Million	€-3.87 Million ≈ $-4.53 Million	-3.050x	-315.12%
2017-12-31	€5.27 Million ≈ $6.16 Million	€-3.87 Million ≈ $-4.53 Million	-0.735x	--

About Maat Pharma SA

PA:MAAT France Biotechnology

Market Cap

$61.16 Million

€52.32 Million EUR

Market Cap Rank

#21104 Global

#331 in France

Share Price

€2.79

Change (1 day)

+0.00%

52-Week Range

€2.36 - €7.78

All Time High

€13.95